President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

In this case, we don't. Semaglutide, the first FDA-approved obesity drug since 2014, has been surging in popularity. Medical experts have deemed the injectable drug a "game changer" in the science ...

Multiple studies have highlighted the glycemic, weight, and cardiac benefits of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA), treatment in patients with or without type 2 ...